Your browser is no longer supported. Please, upgrade your browser.
CDMO Avid Bioservices, Inc. monthly Stock Chart
Avid Bioservices, Inc.
Index- P/E- EPS (ttm)-0.14 Insider Own7.46% Shs Outstand56.52M Perf Week-2.49%
Market Cap504.36M Forward P/E180.00 EPS next Y0.05 Insider Trans-0.14% Shs Float52.38M Perf Month19.05%
Income-7.60M PEG- EPS next Q-0.06 Inst Own67.50% Short Float3.46% Perf Quarter8.56%
Sales69.80M P/S7.23 EPS this Y-54.60% Inst Trans12.58% Short Ratio5.31 Perf Half Y59.29%
Book/sh0.82 P/B10.98 EPS next Y200.00% ROA- Target Price11.33 Perf Year66.98%
Cash/sh0.50 P/C17.89 EPS next 5Y15.00% ROE- 52W Range3.02 - 9.37 Perf YTD17.34%
Dividend- P/FCF- EPS past 5Y33.50% ROI-23.60% 52W High-3.95% Beta2.34
Dividend %- Quick Ratio1.20 Sales past 5Y17.40% Gross Margin16.30% 52W Low198.01% ATR0.40
Employees222 Current Ratio1.50 Sales Q/Q66.00% Oper. Margin- RSI (14)62.97 Volatility4.05% 5.46%
OptionableYes Debt/Eq0.00 EPS Q/Q176.60% Profit Margin- Rel Volume0.86 Prev Close8.95
ShortableYes LT Debt/Eq0.00 EarningsSep 01 AMC Payout- Avg Volume341.16K Price9.00
Recom1.70 SMA208.14% SMA5012.66% SMA20034.33% Volume292,223 Change0.56%
Nov-10-20Initiated KeyBanc Capital Markets Overweight $12
Dec-10-19Upgrade First Analysis Sec Outperform → Strong Buy
Oct-17-19Initiated Stephens Overweight $8
Oct-16-19Initiated Craig Hallum Buy $11
Jun-28-19Upgrade Janney Neutral → Buy $10
May-09-19Downgrade Janney Buy → Neutral
Nov-24-20 04:05PM  
Nov-08-20 08:20AM  
Nov-05-20 10:00AM  
Sep-24-20 09:29AM  
Sep-15-20 04:05PM  
Sep-10-20 10:29AM  
Sep-03-20 07:55AM  
Sep-02-20 07:25AM  
Sep-01-20 06:30PM  
Aug-31-20 04:05PM  
Aug-26-20 08:05AM  
Aug-25-20 04:05PM  
Aug-20-20 08:30AM  
Aug-19-20 11:27AM  
Aug-10-20 09:56AM  
Aug-06-20 08:05AM  
Jul-28-20 08:05AM  
Jul-05-20 06:34PM  
Jul-03-20 12:13PM  
Jul-02-20 01:11PM  
Jul-01-20 08:30AM  
Jun-30-20 11:36PM  
Jun-23-20 04:05PM  
Jun-18-20 12:30PM  
Jun-03-20 04:05PM  
May-06-20 08:05AM  
May-02-20 08:31AM  
Apr-13-20 08:05AM  
Mar-26-20 08:05AM  
Mar-18-20 06:23AM  
Mar-12-20 10:07AM  
Mar-10-20 05:25PM  
Mar-04-20 04:05PM  
Mar-03-20 04:05PM  
Mar-02-20 12:30PM  
Feb-17-20 06:51AM  
Jan-08-20 08:05AM  
Jan-03-20 07:03AM  
Dec-16-19 07:18AM  
Dec-09-19 05:25PM  
Dec-04-19 04:05PM  
Dec-02-19 10:30AM  
Nov-19-19 06:06AM  
Nov-07-19 10:59AM  
Oct-14-19 07:17AM  
Oct-09-19 12:30PM  
Oct-08-19 08:05AM  
Sep-26-19 08:35AM  
Sep-23-19 04:05PM  
Sep-14-19 09:58AM  
Sep-12-19 05:15PM  
Sep-05-19 06:23PM  
Sep-04-19 04:05PM  
Aug-29-19 08:05AM  
Jul-31-19 11:52AM  
Jul-26-19 08:05AM  
Jul-08-19 08:05AM  
Jul-01-19 03:14PM  
Jun-29-19 06:19PM  
Jun-28-19 11:26AM  
Jun-27-19 04:05PM  
Jun-25-19 09:11AM  
Jun-24-19 08:05AM  
Jun-05-19 04:05PM  
May-28-19 08:05AM  
May-20-19 01:27PM  
May-09-19 08:05AM  
May-08-19 04:05PM  
Apr-12-19 07:32AM  
Mar-12-19 12:42PM  
Mar-11-19 07:43PM  
Mar-06-19 04:05PM  
Mar-04-19 08:05AM  
Dec-11-18 06:55AM  
Dec-10-18 05:25PM  
Dec-08-18 10:02AM  
Dec-05-18 04:05PM  
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, purification, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. It serves biotechnology and pharmaceutical companies. Avid Bioservices, Inc. has a process development and manufacturing agreement with Oragenics, Inc. to develop coronavirus vaccine. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ziebell Mark RV. P., General CounselJul 13Sale6.883,68325,3396,829Jul 14 09:25 PM
Hart Daniel RChief Financial OfficerJul 13Sale6.882,05614,14517,983Jul 14 09:24 PM
Walsh Patrick DDirectorMar 23Buy3.2230,00096,60030,000Mar 25 01:09 PM
Hart Daniel RyanChief Financial OfficerMar 16Buy3.777,50028,25512,482Mar 17 12:21 PM
Hancock Richard BInterim President & CEOMar 13Buy3.9912,50049,87522,500Mar 16 03:25 PM
Bamforth Mark RDirectorMar 13Buy4.0126,000104,26026,000Mar 16 03:24 PM
CARLEONE JOSEPHDirectorMar 13Buy4.0112,50050,12566,945Mar 16 03:25 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.